Current trends in treatment and follow-up of patients with differentiated thyroid carcinoma - experience with the use of recombinant human thyrotropin - editorial
2013
Abstract
Differenciated thyroid carcinoma is the most common endocrine malignancy with an excellent prognosis in the case of its early detection. Radioiodine 131I and thyroid hormone continue to be the pivotal dugs in treatment and follow-up fo more than 50 years.
The therapeutical and diagnostic options were recently expanded by the use of recombinant human thyrotropin (rhTSH). Several therapeutic options of in patients with differentiated thyroid carcinoma in relation to stratification of clinical risk are discussed.